![]() | James E BalowFrom the Metabolic Diseases Branch (A.M., J.W., W.F.S., S.K.A., J.E.B., L.S.W.) and the Kidney Diseases Branch (M.A.W., J.E.B.), National Institute of Diabetes and Digestive ... |
KOL Resume for James E Balow (lupus, lupus erythematosus, skin lupus erythematosus, erythematosus, skin)
Year | |
---|---|
2021 | From the Metabolic Diseases Branch (A.M., J.W., W.F.S., S.K.A., J.E.B., L.S.W.) and the Kidney Diseases Branch (M.A.W., J.E.B.), National Institute of Diabetes and Digestive and Kidney Diseases, the Adeno-Associated Virus Biology Section (P.D.B., G.D.P., J.A.C.), Salivary Disorders Unit (B.M.W.), and Skeletal Disorders and Mineral Homeostasis Section (M.T.C.), National Institute of Dental and Craniofacial Research, the Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (M.S.L.), the Symptom Management Branch, National Institute of Nursing Research (B.W.), and the Department of Laboratory Medicine, Clinical Center (S.D.R.), National Institutes of Health, Bethesda, MD; and Kaiser Permanente, Sacramento, CA (Y.S.T.). |
2019 | National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland. |
2016 | Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, Maryland, USA |
2013 | National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland |
2012 | Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Clinical Research Center, Room 5-2551, 20892, Bethesda, MD, USA |
2010 | Kidney Diseases Branch (J.E.B.), National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892; |
2009 | Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham, North Carolina National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Dental and Craniofacial Disorders, National Institutes of Health, Bethesda, Maryland DJ Thurston Professsor O Medicine Director, UNC Kidney Center Professor of Medicine, University of Utah and Veternas Affairs, Salt Lake City Healthcare System |
2008 | National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md Professor, Departments of Medicine, Microbiology and Genetics, University of Alabama at Birmingham, Birmingham, AL, USA Professor of Allergy and Respiratory Medicine, Department of Respiratory Medicine, Brighton General Hospital, Brighton, UK Co-Director of Angiogenesis Program, Lombardi Cancer Institute, Georgetown University |
2007 | Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2National Institute of Diabetes and Digestive and Kidney Diseases, 3Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA and 4Division of Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, 711 10 Heraklion, Greece |
2006 | American College of Rheumatology Committee on Research Liaison *Clinical Endocrinology Branch and †Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland |
2005 | Bethesda, Maryland |
2004 | Columbia University, College of Physicians and Surgeons, New York, New York Georges Pompidou European Hospital, Paris, France Ohio State University, Columbus, Ohio National Institutes of Health, Bethesda, Maryland University of North Carolina School of Medicine, Chapel Hill, North Carolina |
2003 | Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA |
2002 | NIDDK, NIH, Building 10, Room 9N‐222, Bethesda, MD 20892‐1818 From the Metabolic Diseases Branch (MHB, JEB, HAA, JBK), National Institute of Diabetes and Digestive and Kidney Disease, Developmental and Metabolic Neurology Branch (RS, GJM, JMQ, GA, ROB), and Clinical Neurogenetics Unit (LG), National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, and the Armed Forces Institute of Pathology (SGS), Washington, DC. |
2001 | From Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases and Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland; Washington Hospital Center, Washington, D.C.; and Mitretek Systems, McLean, Virginia. |
2000 | USA Genetics and Molecular Biology Branch, National Human Genome Research Institute, Bethesda |
1999 | Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892; The Kidney Disease Section, NIDDK, NIH, Bethesda, Maryland |
1998 | Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, 20892-1818, Bethesda, MD, USA |
1997 | Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Center for Human Genome Research, National Institutes of Health, Bethesda, Maryland, 20892 Kidney Disease Section, National Institutes of Health, Bethesda, MD, USA Graduate Program in Genetics, George Washington University, Washington, DC, 20052 |
1996 | Kidney Disease Section, NIDDK, National Institutes of Health, Bethesda, Maryland, USA. |
1995 | Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases |
1994 | Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases; and the Nursing Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA |
1993 | Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 20892, Bethesda, MD, USA |
1992 | From the Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Md. (E.P., I.A., J.E.B., L.P., A.D.S., D.L.K.) Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 U.S.A. |
1991 | Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892. National Institute of Health, Building 10, Room 9N222, 20892, Bethesda, MD, USA |
1990 | Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; the Department of Medicine, University of Virginia, Charlottesville; the Laboratory of Pathology, National Cancer Institute, National Institutes of Health; and the Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health |
1989 | Kidney Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20892 USA Department of Pediatrics, Kumamoto University, Kumamoto, Japan |
1988 | Kidney Section, NIDDK, National Institutes of HealthUSA Laboratory of Oral Medicine, National Institute of Dental Research, Bethesda, Maryland 20892. |
1987 | Chief, Kidney Disease Section, Arthritis and Rheumatism Branch (ARB) and the Kidney Disease Section (KDS), National Institutes of Arthritis, Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland |
1986 | Laboratory of Human Carcinogenesis and the Laboratory of Tumor Cell Biology, National Cancer Institute, and the Kidney Section, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland |
Prominent publications by James E Balow
OBJECTIVE: Neonatal-onset multisystem inflammatory disease (NOMID; also known as chronic infantile neurologic, cutaneous, articular [CINCA] syndrome) is characterized by fever, chronic meningitis, uveitis, sensorineural hearing loss, urticarial skin rash, and a characteristic deforming arthropathy. We investigated whether patients with this disorder have mutations in CIAS1, the gene which causes Muckle-Wells syndrome and familial cold autoinflammatory syndrome, two dominantly inherited ...
Known for Cias1 Mutations | Nomid Cinca Syndrome | Genetic Heterogeneity | Inflammatory Disease | Onset Multisystem |
OBJECTIVE: Immunosuppressive agents have become the standard of therapy for proliferative lupus nephritis, but some patients may relapse after discontinuing treatment. We reviewed the cases of renal flares in a cohort of patients who participated in 2 randomized controlled clinical trials at the National Institutes of Health and explored the prevalence, outcome, and predictive factors of renal flares.
METHODS: Data were obtained on 145 patients treated with pulse cyclophosphamide, pulse ...
Known for Renal Flares | Immunosuppressive Therapy | Proliferative Lupus Nephritis | Complete Response | Randomized Controlled |
MicroRNAs (miRs) seem to mediate renal fibrosis in several renal diseases, with some miRs having profibrotic effects and others having opposing effects. Although differential expression of certain miRs has been described in lupus nephritis, it is unknown whether miRs contribute to fibrosis or could serve as biomarkers of specific histologic manifestations of lupus nephritis. Here, we compared miR expression in kidney biopsies from patients with lupus nephritis and identified miR-150 as ...
Known for Lupus Nephritis | Renal Fibrosis | Cytokine Signaling Proteins | Mir150 Expression | 1 Protein Suppressor |
Mapping of a Gene Causing Familial Mediterranean Fever to the Short Arm of Chromosome 16
[ PUBLICATION ]
BACKGROUND: Familial Mediterranean fever is an autosomal-recessive disease characterized by acute attacks of fever with sterile peritonitis, pleurisy, or synovitis. The biochemical basis of the disease is unknown, but determining the chromosomal location of the gene for the disorder should be a first step toward defining the biochemical events.
METHODS AND RESULTS: As part of a systematic genome-wide search, we sought evidence of linkage between familial Mediterranean fever and ...
Known for Short Arm | Familial Mediterranean Fever | Chromosome 16 | Lod Score | Genetic Linkage |
CONTEXT: Fabry disease is a metabolic disorder without a specific treatment, caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-gal A). Most patients experience debilitating neuropathic pain and premature mortality because of renal failure, cardiovascular disease, or cerebrovascular disease.
OBJECTIVE: To evaluate the safety and efficacy of intravenous alpha-gal A for Fabry disease.
DESIGN AND SETTING: Double-blind placebo-controlled trial conducted from December ...
Known for Fabry Disease | Alpha Gal | Neuropathic Pain | Enzyme Replacement Therapy | Controlled Trial |
Type 2 diabetes: Evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs
[ PUBLICATION ]
We are conducting a genome scan at an average resolution of 10 centimorgans (cM) for type 2 diabetes susceptibility genes in 716 affected sib pairs from 477 Finnish families. To date, our best evidence for linkage is on chromosome 20 with potentially separable peaks located on both the long and short arms. The unweighted multipoint maximum logarithm of odds score (MLS) was 3.08 on 20p (location, chi = 19.5 cM) under an additive model, whereas the weighted MLS was 2.06 on 20q (chi = 57 ...
Known for Chromosome 20 | Evidence Linkage | 2 Diabetes | Sib Pairs | Human Mellitus |
Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis
[ PUBLICATION ]
Pulse cyclophosphamide is more effective than prednisone alone in preventing renal failure in lupus nephritis. We undertook a randomised, controlled trial to find out whether pulse methylprednisolone could equal pulse cyclophosphamide in preserving renal function in patients with lupus nephritis, and whether there was a difference between long and short courses of pulse cyclophosphamide in preventing exacerbations. 65 patients (60 female, 5 male; median [range] age 29 [10-48] years) with ...
Known for Pulse Methylprednisolone | Severe Lupus Nephritis | Controlled Trial | 6 Months | Renal Function |
OBJECTIVE: To assess the safety of interleukin-6 receptor inhibition and to collect preliminary data on the clinical and immunologic efficacy of tocilizumab in patients with systemic lupus erythematosus (SLE).
METHODS: In an open-label phase I dosage-escalation study, 16 patients with mild-to-moderate disease activity were assigned to receive 1 of 3 doses of tocilizumab given intravenously every other week for 12 weeks (total of 7 infusions): 2 mg/kg in 4 patients, 4 mg/kg in 6 patients, ...
Known for Plasma Cells | Tocilizumab Patients | Monoclonal Antibodies | Lupus Erythematosus | Receptor Inhibition |
James E Balow: Influence Statistics
Concept | World rank |
---|---|
steroids hypertensives | #1 |
diseasecorrective genes | #1 |
illness biopsy humans | #1 |
venules clinician | #1 |
glucocorticosteroids gcs | #1 |
biopsies receiving | #1 |
mnc cml | #1 |
textbook chapters review | #1 |
tgfβ1 mir150 | #1 |
erythematosus1 1this | #1 |
nephritis received | #1 |
pulse immunosuppressive | #1 |
systemic renal vasculitis | #1 |
difference highdose prednisone | #1 |
vasculitic diseases proposals | #1 |
immunoablative cyclophosphamide | #1 |
entry lupus nephritis | #1 |
chapter lupus nephritis | #1 |
genes monoreactive | #1 |
proteinuric nephropathy patients | #1 |
hypercellularity class | #1 |
points proteinuria | #1 |
nephropathy syndromes | #1 |
cyclophosphamide terms | #1 |
chronicity immunosuppressive | #1 |
metreleptin proteinuria | #1 |
chapter renal manifestations | #1 |
lupus nephritis corticosteroids | #1 |
crescents tubular | #1 |
41266f1 | #1 |
criteria pathologic diagnosis | #1 |
cml cytotoxicity tests | #1 |
mirs renal fibrosis | #1 |
proteins biomarkers cytokine | #1 |
nephritis mir150 | #1 |
glomerular capillaries venules | #1 |
renal involvement flares | #1 |
treatment dose corticosteroid | #1 |
ivcy prednisone | #1 |
antidna iga autoantibodies | #1 |
minor residuals cyclophosphamide | #1 |
hyperuricemia azotemia | #1 |
lupus demonstrated | #1 |
proteinuric forms | #1 |
erythematosus severe | #1 |
mpgn composite | #1 |
anticlq antibodies | #1 |
pld egfr | #1 |
1940 hench | #1 |
ivcy csa | #1 |
Open the FULL List in Excel | |
Key People For Lupus Nephritis
James E Balow:Expert Impact
Concepts for whichJames E Balowhas direct influence:Lupus nephritis, Systemic lupus erythematosus, Lupus erythematosus, Systemic lupus, Renal response, Suppressor cells, Pulse cyclophosphamide, Pulse methylprednisolone.
James E Balow:KOL impact
Concepts related to the work of other authors for whichfor which James E Balow has influence:Lupus nephritis, Fabry disease, Sle patients, Familial mediterranean fever, Mycophenolate mofetil, Rheumatoid arthritis, Enzyme replacement therapy.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |